SCHEDULE 13G/A: Sectoral Asset Management and Jerome G. Pfund Disclose Beneficial Ownership in Contineum Therapeutics

Sectoral Asset Management Inc. and Jerome G. Pfund have filed an amended Schedule 13G, disclosing their beneficial ownership of Class A Common Stock in Contineum Therapeutics, Inc., with Pfund holding 4.99% and Sectoral holding 4.2% as of December 31, 2024.

Summary

• Sectoral Asset Management Inc. and Jerome G. Pfund filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership of Class A Common Stock of Contineum Therapeutics, Inc.
• As of December 31, 2024, Jerome G. Pfund beneficially owned 950,786 shares, representing 4.99% of the Class A Common Stock.
• As of the same date, Sectoral Asset Management Inc. beneficially owned 800,787 shares, representing 4.2% of the Class A Common Stock.
• Jerome G. Pfund is identified as the sole control person of Sectoral Asset Management Inc., and his beneficial ownership includes the shares held by Sectoral Asset Management Inc.
• Sectoral Asset Management Inc. is a Canadian corporation, and Jerome G. Pfund is a Swiss citizen.
• The filing indicates that various investment advisory clients of Sectoral Asset Management Inc. and Sectoral Asset Management Limited have the right to receive dividends or proceeds from the sale of these securities, but no single client's interest exceeds five percent.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership, with no inherent positive or negative sentiment.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategy.

Industry Context

This filing is a routine regulatory disclosure in the financial industry, specifically for investment advisors and individuals who acquire significant beneficial ownership in publicly traded companies. It provides transparency regarding major shareholders, which is standard practice across all sectors.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant beneficial owners and their holdings, which can inform investment decisions.
• Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership, ensuring market transparency.

Key Dates

Keywords

Contineum Therapeutics, Beneficial Ownership, Schedule 13G, SEC Filing, Class A Common Stock, Investment Management, Shareholder Disclosure, Sectoral Asset Management, Jerome G. Pfund